ACR Open Rheumatol March 2023 PMID 36762512

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.

Christopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, Enrique R Soriano, Alexa P Kollmeier, Xie L Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S Helliwell

Full text PDF Download social card

Mentions

Peak: 2 in May 2023

across 3 sources since Feb 2023

Extended reach

39,260

potential audience

Total likes

Video views

Mentions per month

Feb 2023 – Oct 2024

Where it's discussed

X / Twitter2 posts
YouTube2 videos
News2 articles

AI synopsis

What people are saying

Several contributions analyze the comparable response rates between TNFi-naive and experienced patients, emphasizing details like 76% and 68% response rates to guselkumab. The tone balances factual reporting and clinical interest, reflecting a moderate but meaningful engagement with the study's implications for treatment approaches.

AgreementModerate agreement

The discussions generally acknowledge the findings, with many agreeing that guselkumab shows promising efficacy in different patient groups.

InterestModerate interest

Participants show moderate interest, discussing specific response rates and treatment schedules, indicating they find the study relevant but not overwhelmingly exciting.

EngagementModerate engagement

Comments often delved into details about the study's outcomes, such as response rates and skin improvements, showing a moderate level of thoughtful engagement.

ImpactModerate impact

The discussions highlight potential impact on treatment strategies for psoriatic arthritis, suggesting that the findings could influence clinical decisions and patient management.

Abstract in brief

The study evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis, regardless of prior treatment with tumor necrosis factor inhibitors, finding that the drug was effective in both groups over one year.
Patients who had never received TNFi responded well, with similar response rates to those who had prior TNFi treatment, and improvements were maintained or increased through 52 weeks.
While overall improvements were comparable, TNF-inhibitor-naive patients experienced greater improvements in physical function and pain, indicating some benefits of guselkumab across different patient histories.]

Read the full abstract

All mentions

Tocilizumab's Role in Improving Giant Cell Arteritis Treatment

Tocilizumab is used to treat Giant Cell Arteritis, an inflammatory large vessel disease. Recent research indicates it controls symptoms more effectively with fewer side effects compared to steroids, improving disease…

ReumaTimes · May 1, 2023 24 views

Tocilizumab Enhances Giant Cell Arteritis Treatment Effectiveness

Tocilizumab is a medication used to treat Giant Cell Arteritis, an inflammatory condition affecting large blood vessels. Recent research shows it can better control symptoms with fewer side effects than steroids…

ReumaTimes · Oct 17, 2024 0 views

ACR_Journals

@ACR_Journals · X

Mar 24, 2023 · 2 likes · 2 shares · 14,300 followers View post →

Dr. John Cush

@RheumNow · X

Feb 14, 2023 · 3 likes · 24,912 followers View post →

American College of Rheumatology Reading Room | Multidomain ...

News

... : Analysis of the phase 3, randomized, placebo-controlled DISCOVER-1 study" ACR Open Rheumatol 2023; DOI: 10.1002/acr2.11523. 1. 1 Comment.

May 26, 2023 View →

Guselkumab Delivers Long-Term Improvements in TNF-Naïve, TNF ...